olivLaw · US equity research
Janux Therapeutics, Inc. JANX
Pharmaceutical Preparations · SIC 2834 · Vertical: Pharmaceutical Preparations (SIC 2834)
Janux Therapeutics is a clinical-stage biopharmaceutical company developing immunotherapies based on proprietary tumor-activated T cell engager platforms, with a focus on prostate cancer. The company has no product revenue yet, and its net loss of $113.6 million in fiscal 2025 and cash position of $970.9 million at mid-2026 define its current stage of funding and clinical development.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 05 Nov 2026, Janux Therapeutics, Inc. (JANX) stock was 16.06 USD (−11.66% on the day), with market capitalisation 982.6 m USD, beta 1.22, 52-week range 12.18–34.74 USD. Latest reported quarter (Q3 2026): revenue of 9.3 m USD (−7.1% YoY), net income of -21.6 m USD, diluted EPS -0.34 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 40.4
- weak (30–45)
- Bollinger (20, 2)
- 16.09 – 18.52
- below the lower band · %B -0.01 · band width 14.0%
- SMA 50 / 200
- 17.52 / 15.40
- mixed trend
- MACD (12, 26, 9)
- 0.01 / 0.03
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −4.3% | −5.9% | +1.6 pp | — |
| 3 months | −0.2% | −4.6% | +4.4 pp | — |
| 6 months | +10.5% | +0.2% | +10.2 pp | — |
| Year to date | +16.4% | +7.4% | +9.0 pp | — |
| 1 year | −41.7% | +8.2% | −49.9 pp | +4.8% |
| 3 years | +157.0% | +68.4% | +88.5 pp | +38.9% |
| 5 years | −41.2% | +56.5% | −97.7 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q3 2026 · 30 Sept 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 10.0 m | 0 | 3.7 m | 10.3 m | 9.3 m |
| Research & development | 20.8 m | 25.1 m | 34.7 m | 34.6 m | 31.5 m | 26.8 m | 31.0 m | 30.6 m |
| Operating income | -29.0 m | -34.9 m | -45.1 m | -35.3 m | -42.4 m | -34.2 m | -31.7 m | -31.3 m |
| Net income | -20.2 m | -23.5 m | -33.9 m | -24.3 m | -31.9 m | -24.4 m | -22.0 m | -21.6 m |
| Diluted EPS | -0.36 ≈ | -0.38 | -0.55 | -0.39 | -0.51 ≈ | -0.39 | -0.35 | -0.34 |
| Operating cash flow | -16.7 m | -17.0 m | -23.8 m ≈ | -12.9 m ≈ | -28.5 m | -12.3 m | 12.5 m ≈ | -25.2 m ≈ |
| Capex | 42.0 k | 371.0 k | 473.0 k ≈ | 93.0 k ≈ | 106.0 k | 273.0 k | 202.0 k ≈ | 2.0 k ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 3.6 m | 8.6 m | 8.1 m | 10.6 m | 10.0 m |
| Revenue YoY | unavailable | unavailable | +136.8% | −6.1% | +31.0% | −5.6% |
| Net income | -6.8 m | -32.7 m | -63.1 m | -58.3 m | -69.0 m | -113.6 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | -1.39 | -1.52 | -1.32 | -1.28 | -1.83 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | unavailable | -898.3% | -732.2% | -721.2% | -651.6% | -1,136.3% |
| Free cash flow | -4.4 m | -18.5 m | -49.4 m | -52.4 m | -44.2 m | -83.3 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 52.3 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 956.8 m USD
- Total assets
- 1.0 bn USD
- Debt / equity
- unavailable
- Current ratio
- 39.04x
- ROE
- -11.5%
- ROA
- -11.0%
- FCF margin
- -832.8%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 3.6 m | 8.6 m | 8.1 m | 10.6 m | 10.0 m | SEC (XBRL)· 26 Feb 2026verified |
| Research & development | 3.0 m | 26.2 m | 53.4 m | 54.9 m | 68.4 m | 125.9 m | SEC (XBRL)· 26 Feb 2026verified |
| Operating income | -4.8 m | -32.9 m | -67.1 m | -73.0 m | -98.8 m | -157.7 m | SEC (XBRL)· 26 Feb 2026verified |
| Income tax | — | — | — | 0 | 0 | 0 | SEC (XBRL)· 26 Feb 2026verified |
| Net income | -6.8 m | -32.7 m | -63.1 m | -58.3 m | -69.0 m | -113.6 m | SEC (XBRL)· 26 Feb 2026verified |
| Diluted EPS | — | -1.39 | -1.52 | -1.32 | -1.28 | -1.83 | SEC (XBRL)· 26 Feb 2026verified |
| Weighted average diluted shares | — | 23.5 m | 41.5 m | 44.0 m | 53.8 m | 62.0 m | SEC (XBRL)· 26 Feb 2026verified |
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 7.8 m | 35.6 m | 51.4 m | 19.2 m | 430.6 m | 52.3 m | SEC (XBRL)· 26 Feb 2026verified |
| Receivables | 8.0 m | 0 | 0 | 0 | — | — | SEC (XBRL)· 08 Mar 2024verified |
| Current assets | 16.1 m | 377.0 m | 332.4 m | 349.2 m | 1.0 bn | 975.9 m | SEC (XBRL)· 26 Feb 2026verified |
| Property, plant & equipment, net | 155.0 k | 1.4 m | 7.1 m | 7.0 m | 4.9 m | 3.9 m | SEC (XBRL)· 26 Feb 2026verified |
| Total assets | 16.2 m | 379.8 m | 364.0 m | 380.4 m | 1.1 bn | 1.0 bn | SEC (XBRL)· 26 Feb 2026verified |
| Accounts payable | 428.0 k | 2.5 m | 2.2 m | 2.4 m | 4.0 m | 5.0 m | SEC (XBRL)· 26 Feb 2026verified |
| Current liabilities | 3.2 m | 12.8 m | 16.5 m | 13.0 m | 17.5 m | 25.0 m | SEC (XBRL)· 26 Feb 2026verified |
| Total liabilities | 9.2 m | 13.5 m | 43.3 m | 36.1 m | 38.7 m | 44.7 m | SEC (XBRL)· 26 Feb 2026verified |
| Equity | -14.6 m † | 366.3 m † | 320.7 m † | 344.3 m † | 1.0 bn † | 956.8 m † | SEC (XBRL)· 26 Feb 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -4.4 m | -17.0 m | -42.9 m | -50.6 m | -43.8 m | -82.2 m | SEC (XBRL)· 26 Feb 2026verified |
| Capex | 0 | 1.5 m | 6.4 m | 1.9 m | 359.0 k | 1.0 m | SEC (XBRL)· 26 Feb 2026verified |
| Free cash flow | -4.4 m ≈ | -18.5 m ≈ | -49.4 m ≈ | -52.4 m ≈ | -44.2 m ≈ | -83.3 m ≈ | SEC (XBRL)· 26 Feb 2026derived |
| Investing cash flow | 0 | -341.0 m | 58.3 m | -41.2 m | -258.0 m | -301.0 m | SEC (XBRL)· 26 Feb 2026verified |
| Financing cash flow | 11.5 m | 386.5 m | 500.0 k | 59.5 m | 713.2 m | 4.9 m | SEC (XBRL)· 26 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 4 of at least 6
- score weight coverage: 27.1% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
05 Nov 2026Source: olivLaw, closing series
Market cap: 982.6 m USD
Key indicators
Coverage and freshness
Score by group
27% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 4 of at least 6; score weight coverage: 27.1% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -428.7% | 21 (vs peers) | 23% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 5.1% | 43 (on a fixed band) | 31% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 17.7x | 100 (on a fixed band) | 15% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -5.5% | 0 (on a fixed band) | 31% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial100/100 · 1/3 factors with a value
- Growth· partial43/100 · 1/2 factors with a value
- Quality· partial21/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Janux Therapeutics, Inc. (JANX). Latest full fiscal year: 2025; data up to 2026-09-30.
Figures computed from the financial statements: revenue 10.0 m USD in 2025; YoY growth -5.6%; net margin -428.7%; ROE -10.6%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 4 of at least 6; score weight coverage: 27.1% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 17.7x
What contradicts it
- Net margin: -428.7%
- FCF yield: -5.5%
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Pharmaceutical Preparations (SIC 2834) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| LLYEli Lilly And Company | 1,283.9 bn | 44.3 | 86.1% | 31.9% | +44.7% | +27% / +131% |
| JNJJohnson & Johnson | 655.6 bn | 41.3 | 20.0% | 16.2% | +6.0% | +32% / +76% |
| ONCBeone Medicines Ltd. | 575.0 bn | 640.9 | 18.4% | 13.9% | +40.2% | +14% / +107% |
| ABBVAbbVie Inc. | 509.5 bn | 49.6 | — | 15.7% | +8.6% | +27% / +102% |
| MRKMerck & Co., Inc. | 362.2 bn | 151.2 | 5.1% | 3.6% | +1.3% | +40% / +43% |
| ABTAbbott Laboratories | 196.7 bn | 42.3 | 9.2% | 9.7% | +5.7% | −12% / +9% |
| PFEPfizer Inc | 170.3 bn | 42.6 | 4.4% | 6.3% | −1.6% | +16% / −2% |
| VRTXVertex Pharmaceuticals Inc | 137.5 bn | 34.9 | 20.8% | 30.7% | +8.9% | +25% / +53% |
| BMYBristol-Myers Squibb Company | 129.0 bn | 14.0 | 44.1% | 18.5% | −0.2% | +28% / +28% |
| TEVATeva Pharmaceutical Industries Limited | 48.8 bn | 97.3 | 6.6% | 3.6% | +4.3% | +55% / +325% |
| ZTSZoetis Inc. | 33.4 bn | 13.8 | 57.6% | 26.4% | +2.3% | −36% / −54% |
| ROIVRoivant Sciences Ltd. | 26.5 bn | — | -6.2% | -3,535.0% | −71.6% | +76% / +283% |
| RPRXRoyalty Pharma plc | 26.2 bn | 47.7 | 6.9% | 25.7% | +5.1% | +69% / +150% |
| UTHRUnited Therapeutics Corporation | 24.1 bn | 21.3 | 19.1% | 38.6% | +10.6% | +16% / +136% |
| INSMInsmed Inc | 23.9 bn | — | -72.5% | -39.9% | +66.7% | −48% / +335% |
| VTRSViatris Inc. | 21.7 bn | — | -24.3% | -23.9% | −3.0% | +77% / +107% |
| ALNYAlnylam Pharmaceuticals, Inc. | 21.0 bn | 7.9 | 126.6% | 52.8% | +65.2% | −65% / −7% |
| IDYAIDEAYA Biosciences, Inc. | 3.0 bn | — | -38.5% | -1,149.6% | +3,024.4% | −14% / −3% |
| RCUSArcus Biosciences, Inc. | 2.5 bn | — | -114.1% | -453.0% | −4.3% | −32% / +17% |
| STOKStoke Therapeutics, Inc. | 1.7 bn | — | -73.6% | -862.1% | +404.5% | −16% / +588% |
| INVAInnoviva, Inc. | 1.4 bn | 9.7 | 17.0% | 44.1% | +14.7% | −11% / +39% |
| JANXJanux Therapeutics, Inc. | 982.6 m | — | -10.6% | -428.7% | −5.6% | −42% / +157% |
| WVEWave Life Sciences, Inc. | 635.1 m | — | -80.0% | -296.9% | −60.5% | −59% / −39% |
| NGNENeurogene Inc. | 513.3 m | — | -45.3% | — | −100.0% | +22% / +85% |
| DMACDiaMedica Therapeutics Inc. | 487.5 m | — | -114.6% | — | unavailable | +5% / +270% |
1- and 3-year price returns: for JANX from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 06 Aug 2026; since then the company filed 8-K (05 Nov 2026 · results), 10-Q (05 Nov 2026).
In brief
Janux Therapeutics is a clinical-stage biopharmaceutical company developing immunotherapies based on proprietary tumor-activated T cell engager platforms, with a focus on prostate cancer. The company has no product revenue yet, and its net loss of $113.6 million in fiscal 2025 and cash position of $970.9 million at mid-2026 define its current stage of funding and clinical development 123.
SWOT
Strengths
- Proprietary platform technologies with masking and tumor-activation mechanisms, supported by a solid liquidity position.
- Collaborations with large pharmaceutical companies that bring upfront payments and potential milestones.
- A clinical portfolio with several programs at different stages, from Phase 1 to advanced preclinical.
Weaknesses
- No product sales revenue and recurring net losses in past years.
- Most programs remain in preclinical or early clinical stages, with limited experience in human trials.
- Dependence on future clinical events to validate the TRACTr technology.
Opportunities
- Success in solid tumors could significantly widen the addressable market for T cell engagers.
- Extending the ARM platform to autoimmune disease could open a new market.
- New collaborations or milestones from existing partnerships could bring additional funding.
Threats
- Early clinical results are not always predictive of later outcomes, and studies can fail.
- Competition in T cell engagers for prostate cancer is intense, and other companies may advance faster.
- If capital markets deteriorate, additional funding could become more expensive or unavailable.
Risks
- No product revenuehigh
The company has not commercialized any product, and its revenue depends on collaborations and future approvals that may not materialize.
- Need for additional capitalhigh
The company estimates that existing liquidity will not be sufficient to take its products through approval, which could lead to dilution or restrictions.
- Uncertain clinical resultshigh
Early-stage data do not guarantee success in later studies, and safety could limit dosing.
- Dependence on partnersmedium
If Merck or Bristol Myers Squibb stops the collaboration, the company may lose milestone and royalty payments.
- Macroeconomic and geopolitical risklow
Trade tensions and market volatility could affect access to financing and operating costs.
Investment thesis
What would need to be true (bull case)
- If clinical data for JANX007 remain durable, the company could demonstrate the value of its TRACTr platform in prostate cancer.
- A solid balance sheet and collaborations with large pharmaceutical companies could support several programs in parallel.
- Extending the ARM platform to autoimmune disease could add a new segment with high market potential.
What would break the thesis
- The company has no approved products yet, and net losses could continue for many years.
- If clinical results fail to hold in later stages, the value of the platform could be called into question.
- The need for additional funding could lead to dilution of existing shareholders.
What to watch
- Clinical data for JANX011 in the healthy volunteer studysecond half 2026
- Clinical initiation of JANX013 (PSMA TRACIr with CD28)second half 2026
- Additional clinical data for JANX007 at a medical congressfirst half 2027
- Trend in liquidity and capital needs in upcoming reportsQ3 2026
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 06 Aug 2026; since then the company filed 8-K (05 Nov 2026 · results), 10-Q (05 Nov 2026).
The business
Janux Therapeutics develops a pipeline of immunotherapies on its proprietary TRACTr, TRACIr and ARM platforms, which aim to redirect T cells against tumors with reduced toxicity. Its lead candidate, JANX007, a PSMA-targeted TRACTr, is in a Phase 1 study in patients with metastatic castration-resistant prostate cancer 12. The company has reported net losses every year since inception and has no product sales, with its revenue coming from collaborations with Merck and Bristol Myers Squibb 12.
Segments
TRACTr platform and oncology programs
The TRACTr platform produces T cell engagers with a tumor antigen-binding domain and a CD3 binding domain, masked by peptides that activate the molecule only inside tumors. Clinical programs include JANX007 (PSMA) and JANX008 (EGFR), and JANX014, a double-masked PSMA TRACTr, entered clinical evaluation in April 2026 12.
ARM platform for autoimmune disease
The ARM platform redesigns bispecific T cell engagers to deplete B cells rapidly and durably, aiming for a long-lasting immune reset in autoimmune disease. Its lead candidate, JANX011 (CD19-ARM), is in a Phase 1 study in healthy volunteers, initiated in February 2026 12.
Market context
The company operates in the cancer immunotherapy market, where T cell engagers have shown strong anti-tumor activity in blood cancers but face challenges in solid tumors due to cytokine release syndrome and short half-life 1. Success in solid tumors could significantly widen the addressable market, but the company has no approved products yet 12.
Trends
- Interest in T cell engagers for solid tumorstailwind
T cell engagers are an emerging class of off-the-shelf immunotherapies that could avoid the complex manufacturing of autologous CAR-T therapies 1. This interest may support collaborations and financing for companies in this segment 1.
- High cost of clinical developmentheadwind
Biopharmaceutical development is capital intensive, and the company expects research and development expenses to rise, which could require new funding sources 12.
- Partnerships with large pharmaceutical companiesmixed
Agreements with Merck and Bristol Myers Squibb bring upfront payments and potential milestones, but they can also limit the company's rights over certain products 13.
- Macroeconomic and geopolitical uncertaintyheadwind
Trade tensions, geopolitical conflicts and volatility in credit markets could affect access to capital and operating costs 12.
Competitive position
Janux competes with other companies developing T cell engagers and bispecific therapies for prostate cancer and solid tumors, as well as with developers of autoimmune therapies using similar approaches. The available sources do not identify competitors in detail, so a relative assessment of position would require additional data 1.
- Merck Sharp & Dohme (partner and potential competitor in T cell engagers)
The company has an exclusive collaboration with Merck for T cell engagers outside its internal pipeline, making it both a partner and an actor in the same segment 1.
- Bristol Myers Squibb (collaboration partner)
The January 2026 collaboration transfers development and commercialization of a candidate to the partner, while Janux remains involved through the first Phase 1 study 1.
- Developers of PSMA-targeted T cell engagers for prostate cancer
The source mentions other companies developing PSMA T cell engagers with less frequent dosing, indicating direct competition in the lead indication 1.
- Developers of T cell engagers in autoimmune disease
The source mentions T cell engager studies in rheumatoid arthritis, suggesting competition in the company's ARM segment 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Quarterly report05 Nov 2026
- Current report05 Nov 2026Results of operations · Financial statements and exhibits
- Quarterly report06 Aug 2026
- Current report06 Aug 2026Results of operations · Financial statements and exhibits
- Current report23 Jun 2026Other events
- Current report12 Jun 2026Shareholder vote
- Quarterly report07 May 2026
- Current report07 May 2026Results of operations · Financial statements and exhibits
- Current report28 Apr 2026Departure or appointment of officers
- Proxy statement28 Apr 2026
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Janux Therapeutics, Inc. · 26 Feb 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Janux Therapeutics, Inc. · 06 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Janux Therapeutics, Inc. · 06 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.